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A B S T R A C T
Some social surveys now collect physical measurements and markers derived from biological samples, in
addition to self-reported health assessments. This information is expensive to collect; its value in medical
epidemiology has been clearly established, but its potential contribution to social science research is less
certain. We focused on disability, which results from biological processes but is defined in terms of its
implications for social functioning and wellbeing. Using data from waves 2 and 3 of the UK Understanding
Society panel survey as our baseline, we estimated predictive models for disability 2–4 years ahead, using
a wide range of biomarkers in addition to self-assessed health (SAH) and other socio-economic
covariates. We found a quantitatively and statistically significant predictive role for a large set of nurse-
collected and blood-based biomarkers, over and above the strong predictive power of self-assessed
health. We also applied a latent variable model accounting for the longitudinal nature of observed
disability outcomes and measurement error in in SAH and biomarkers. Although SAH performed well as a
summary measure, it has shortcomings as a leading indicator of disability, since we found it to be biased
in the sense of over- or under-sensitivity to certain biological pathways.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
An important recent development in research based on large-
scale social surveys is the integration of physical health* Corresponding author at: ScHARR, University of Sheffield, 30 Regent Street, S1
4DA, United Kingdom.
E-mail address: steve.pudney@sheffield.ac.uk (S. Pudney).
http://dx.doi.org/10.1016/j.ehb.2019.100814
1570-677X/© 2019 The Authors. Published by Elsevier B.V. This is an open access articmeasurements and markers derived from biological samples, in
addition to traditional self-reported health assessments. Biomark-
ers are objectively measured and evaluated as indicators of normal
biological or pathogenic processes (Colburn et al., 2001), and they
have potential advantages over self-assessments as early indica-
tors of conditions that are below clinical diagnostic thresholds, or
are pre-symptomatic and below individuals’ threshold of percep-
tion (Colburn et al., 2001). Cardiovascular, metabolic, inflammato-
ry, neuroendocrine and other biomarkers have been shown to be
predictors of mortality and morbidity when used alone or
alongside self-reported health assessments (Idler and Benyamini,
1997; Gruenewald et al., 2006; Ridker, 2007; Jylhä, 2009; Doiron
et al., 2015). They have also been used to reveal the socioeconomic
gradient in health risks (Seeman et al., 2004; Lee et al., 2015;
Carrieri and Jones, 2017).
Despite their advantages, biomarkers impose significant
additional costs of collection in the survey context and their
potential contribution to economic and social research is not
entirely clear. The wider social impacts of ill-health – on quality of
life, personal and social functioning, and social costs of disease –
depend critically on the duration and severity of disability prior to
death, and there has been little research on the role of biomarkers
in relation to disability. Disability is associated with loss of
employment, early retirement and serious consequences for the
families affected (Pudney et al., 2011; Jones, 2016; Christensen and
Gupta, 2017) and typically implies long-lasting impairments thatle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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This is particularly so in the UK where disability prevalence is well
above the European Union average (Jones, 2016) and has been
rising rapidly (from 11.9 to 13.3 million over 2013/14–2015/16
(DWP, 2017). There is evidence of an increasing birth-cohort trend
in functional difficulties for older individuals of low socio-
economic status (Morciano et al., 2015) and developed countries
like the UK may face severe problems in supporting the projected
future growth in the disabled population and providing public
support to people with care needs (Commission on Funding of Care
and Support, 2011). A crucial question for researchers and
policymakers is whether the demand for care services will be
curbed by gains in disability-free life expectancy alongside the
projected continuing gains in longevity. An answer to this question
requires a better understanding of the processes leading to
disability, allowing the development of strategies and screening
programmes to address disability more efficiently. The availability
of biomarker information in population-representative data may
contribute to that better understanding.
Despite the importance of disability trends for social policy
planning, relatively little is known about the association between
biomarkers and future disability. The World Health Organization
(WHO) proposed a framework that portrays progression from
diseases to functional disabilities (WHO, 1980), and Fried et al.
(1991) hypothesized the existence of pre-clinical disability as an
intermediate stage in which health impairments have an impact on
general functioning. Few studies have explored the predictive role
of biomarkers in relation to this disability process, and most are
limited by being based on small samples or unrepresentative data
(Brex et al., 2002; Reuben et al., 1999; Baylis et al., 2013; Seeman
et al., 1994; Kallaur et al., 2017); or focused exclusively on older
individuals (Reuben et al., 1999; Seeman et al., 1994; Baylis et al.,
2013); or concerned with disability outcomes from a specific
disease or condition (Brex et al., 2002; Kallaur et al., 2017). Another
study by Pagan et al. (2016) tests the hypothesis that disability is a
potential mediator in the link between obesity and job satisfaction.
We examined the predictive power of a wide range of
biomarkers for future disability and specifically asked whether
biomarkers offer incremental value in predicting disability out-
comes beyond the contribution of the conventional self-assessed
health (SAH) measure. SAH may be associated with disability
outcomes in parallel with biomarkers by reflecting the impact on
the individual of diagnosis of health conditions defined in terms of
elevated biomarkers (Idler et al., 2004; Jylhä, 2009), or through
bodily sensations that are sensitive to the biochemical processes
measured by biomarkers (a, 2009). Besides confirming the value of
biomarkers as leading indicators of disability, we also investigated
the success of SAH as an overall summary of biomedical states
relevant to disability and examined whether SAH is biased in the
sense of over- or under-sensitivity to specific biological pathways.
The paper makes several new contributions to the research
literature. To the best of our knowledge, this is the first study that
provides a comprehensive analysis of this kind. Using baseline data
from early waves of the UK Household Longitudinal Study (UKHLS,
also known as Understanding Society), we estimate predictive
models for disability two to four years ahead, exploiting a large set
of nurse-collected and blood-based biomarkers. These biomarkers
measure adiposity, grip strength, blood pressure, lung, kidney and
liver functions, inflammation, steroid hormone levels, blood sugar
and anaemia, giving an unusually broad picture of individuals’
health states. The use of several alternative disability measures
demonstrates the robustness of our results.
In addition to simple prediction models, we also develop a
latent variable (LV) approach which is new to the literature. This LV
model has a number of advantages. First, unlike simpler prediction
models, it takes into account the longitudinal nature of our data ondisability, allowing for correlation between disability variables two
to four years after baseline. Second, it addresses measurement
error bias by allowing for measurement noise in both SAH
(Crossley and Kennedy, 2002) and the biomarkers (Zang et al.,
2015). Measurement error in biomarkers normally causes attenu-
ation of the estimated impact of the biological pathways on
disability, and the LV model is expected to give more accurate
estimates of these impacts. This may be of particular importance
for developing policy strategies and interventions to reduce the
personal and social burden of disability. Third, our LV approach is
set up to identify any distinct dimension of health which influences
future disability and is captured by the biomarkers but missed by
SAH. The pattern of factor loadings tells us what underlying aspects
of health tend to be under- or over-represented by the SAH
measure and can therefore guide the interpretation of research
findings related to SAH.
2. Data
The UKHLS is a large, nationally representative panel survey,
running continuously from the initial wave in 2009–10, with each
panel member interviewed annually. Its predecessor, the British
Household Panel Survey (BHPS) was incorporated into the UKHLS
from wave 2. A set of physical health measures and non-fasted
blood samples were collected by nurses, five months on average
after the wave 2 interview for UKHLS respondents and similarly at
wave 3 for the BHPS sample (McFall et al., 2014). Respondents
were eligible for nurse visits if, at the relevant wave, they were
aged 16 or over, lived in England, Wales or Scotland and were not
pregnant. Blood sample collections were further restricted to
those who had no clotting or bleeding disorders and no history of
fits. Participants gave informed written consent for their blood to
be taken and stored for future scientific analysis. The UKHLS has
been approved by the University of Essex Ethics Committee and
the nurse data collection by the National Research Ethics Service
(10/H0604/2).
We define wave 2 as the baseline for the main UKHLS panel and
wave 3 as the baseline for the BHPS sub-panel and we refer to the
timing of this baseline observation as t = 0; these baseline
observations were spread through calendar years 2010–2013.
We used baseline data on personal and household characteristics
and bio-medical measures as predictors of disability observed
subsequently at waves 4–6 for the UKHLS sample (t = 2, . . . 4) or
waves 5–6 for the BHPS sample (t = 2, 3), where t denotes years
since the baseline main interview. We did not use data from t = 1
since the time gap between collection of biomarkers and interview
at t = 1 was less than 6 months for 75% of the t = 1 sample.
There were 15,632 and 5053 UKHLS and BHPS respondents who
participated in the wave 2 or wave 3 nurse visits. For the UKHLS
group, 13,404, 12,719 and 11,434 were followed up at waves 4, 5
and 6 respectively and had non-missing information on disability;
4513 and 4113 of the BHPS subsample were followed up at waves 5
and 6. We further conditioned the analysis on the absence of
reported disability at baseline by excluding those reporting the
relevant type of disability at baseline. Exclusion of these cases
reduced the potential samples by 25%, 13% and 8% depending on
the disability concept used. A detailed summary of available
sample sizes is given in the Supplement Table S1.
2.1. Biomarkers
Measures of adiposity, grip strength, heart rate, blood pressure
and lung function were collected during visits by trained nurses.
We used the waist-to-height ratio (WHR) to measure adiposity.
Grip strength was measured (in kg) using a hand dynamometer
(McFall et al., 2014) and we took the highest reading from three
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grip strength are indicative of better physical functioning.
Three repeated measurements of resting heart rate (HR),
systolic and diastolic blood pressure (SBP, DBP) were taken at
intervals of one minute (McFall et al., 2014). We skipped the first
reading, believed to impose upward biases, and computed HR, SBP
and DBP as the average of the second and third readings. HR, which
is sometimes regarded as a measure of fitness rather than health,
was used as a continuous variable, and we also used a binary
hypertension indicator recording SBP > 140, DBP > 90 and/or
current use of anti-hypertensive medications (Johnston et al.,
2009).
Lung function, assessed using spirometry equipment, was
measured by the total amount of air forcibly blown out after a full
inspiration (forced vital capacity; FVC), higher values indicating
better lung function (Gray et al., 2013). Forced expiratory volume in
one second (FEV1) is often used as an alternative to FVC. However,
different equipment and measurement protocols were used in
Scotland than in England and Wales, and comparison of matched
samples showed FEV1 to be seriously affected by this, while FVC
measures appeared comparable. Consequently we retained the
Scottish sample and used FVC as our lung function measure.
We used blood-based biomarkers specific to inflammation,
steroid hormone, cholesterol, blood sugar, kidney function, liver
function and anaemia.
C-reactive protein (CRP) rises as part of the immune response to
infection and is associated with general chronic or systemic
inflammation. We excluded those with a CRP over 10 mg/L,
because those values may reflect current transient infections
rather than chronic processes (Pearson et al., 2003).
Dihydroepiandrosterone suphate (DHEAS) is the most common
steroid hormone in the body, considered as one of the primary
mechanisms through which psychosocial stressors may affect
individual health. Low levels of DHEAS are associated with
cardiovascular (CVD) risks and all-cause mortality (Ohlsson
et al., 2010).
High-density lipoprotein cholesterol (HDL) is known as “good”
cholesterol, low levels being associated with increased CVD risks
(Wannamethee et al., 2000).
Glycated haemoglobin (HbA1c) measures blood sugar, and is
regarded as a validated diagnostic test for diabetes (WHO, 2011).
The estimated glomerular filtration rate (EGFR), calculated from
the serum creatinine concentration, measures kidney function;
higher EGFR levels indicate better kidney function (Levey et al.,
2009).
We used albumin, the main protein made by the liver, as a liver
function test; low albumin levels suggest impaired liver function
(Howard and Sparks, 2016).
Haemoglobin (Hgb), is an iron-containing protein responsible
for carrying oxygen throughout the body, and was used to proxy
anaemia status; lower levels of Hgb are suggestive of anaemia
(Balarajan et al., 2012).
In addition to specific markers, we also used two composite
summary measures. One was an index of multi-system risk that
measures the wear and tear on the body, approximating the
allostatic load (Seeman et al., 2008). Our index combined the
selected biomarkers for inflammation, blood pressure, HR, HbA1c,
HDL cholesterol, albumin, DHEAS and the WHR (Seeman et al.,
2008; Howard and Sparks, 2016). HDL, Albumin and DHEAS were
converted to negative values to reflect ill health, and then each
biomarker was transformed into z-scores and summed to calculate
the overall index. The second index was a cumulative risk score for
CVD, created by adding the relevant z-scores for WHR, blood
pressure, HbA1c and CRP (Walsemann et al., 2016). A summary of
all biomarkers by reported future disability state is given in the
Supplement Tables S3 and S4.2.2. Self-assessed health
SAH is considered a summary measure capturing the way that
numerous aspects of health, both subjective and objective, are
combined within the perceptual framework of the individual
respondent (a, 2009). The SAH question asked respondents to rate
their health on a five-point scale from “excellent” to “poor”. It was
collected in the self-completion instrument at baseline, approxi-
mately five months prior to biomarker collection. We group the
lowest two SAH categories because of their small sample size,
giving a four-point scale ranging from 1 = “excellent” to 4 = “fair” or
“poor”.
2.3. Disability measures
Our measures of disability were collected at UKHLS waves 4–6,
so disability outcomes were observed for prediction horizons of t
= 2 . . . 4 years for the main UKHLS sample or t = 2, 3 years for
BHPS respondents. Respondents were asked about any long-
standing physical or mental impairment that they might have and
then the consequent functional difficulties, from a list of twelve
provided (see Supplement Table S2 for the full list). We used the
report of any functional difficulty as a dichotomous variable and
the number of functional difficulties (coded as an ordinal variable:
0, 1, 2 or 3+) as an indicator of severity. Specific difficulty with
mobility is also examined as a separate dichotomous indicator
because of its relatively high prevalence and significance for
functioning and independence in later life (Guralnik et al., 1993).
Our fourth disability measure came from the income module of
the UKHLS questionnaire, constructed as a binary indicator of
whether the respondent received income from private disability
insurance or any of the UK disability benefit programmes. For all
programmes, receipt requires a decision to apply for the benefit,
the ability to craft a good-quality application and a positive
assessment of need by the programme administrators. Conse-
quently, while the benefit receipt indicator involves a rigorous
external assessment of severity, that assessment is confounded to
some degree by the incentive and capacity to apply for the benefit,
which has a strong socioeconomic gradient (Hancock et al., 2016).
2.4. Covariates
The explanatory covariates that we used in our models have
been found to be associated with disability (Hernández-Quevedo
et al., 2008; Morciano et al., 2015), and also directly with
biomarkers (Carrieri and Jones, 2017). The covariates were
collected at baseline and are described and summarised in the
Supplement Table S5. Gender and polynomials in age were used to
capture demographic influences. Three indicators of socio-
economic status were included: educational attainment, home
ownership and household income. We excluded disability benefits
from income to avoid spurious correlation arising from the fact
that disability creates eligibility for those benefits (see Morciano
et al. (2015)). We also controlled for marital status, household
composition, national and urban dummies. To assess the impact on
future disability of lung function over and above smoking status,
we estimated models with and without the inclusion of smoking
variables.
3. Methods
Our analysis uses a sample of individuals who had no observed
history of disability at baseline defined as the time of biomarker
collection (t = 0). Conditioning the analysis in this way focuses
attention on the transition from full physical functioning to
disability, and it avoids the complications raised by the fact that, for
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evolution of their health and disability prior to joining the
Understanding Society panel.
We apply two types of statistical models. First, in line with
much of the health literature, we apply standard predictive models
for the incidence of disability at a post-baseline horizon. Define Di4
to be any one of three binary indicators of disability status
(reported mobility difficulty; any reported functional difficulty;
receipt of disability benefit) four years after baseline. For each
indicator we applied a probit prediction model:
Pr Di4 ¼ 1jXi0; Si0; Bi0ð Þ ¼ F a0 þ a1Bi0 þ a2Si0 þ a3Xi0 þ uitð Þ ð1Þ
where F() is the N(0, 1) distribution function. Bi0 is a specific
biomarker or an index of biomarkers observed at the nurse visit at
baseline t = 0; Si0 is a set of dummy variables representing SAH in
period 0; Xi0 is a set of covariates describing the individual and her/
his history up to the nurse visit; uit is a random residual; and α0
. . . α3 are coefficients. Note that the use of a 4-year horizon
excludes BHPS members who received the nurse visits at wave 3;
however, they were included in the LV model presented later in
this section.
In addition to the three binary indicators, we also extended
model (1) to analyse the reported number of functional difficulties
as a 4-level ordered probit model. Average marginal impacts of
SAH and biomarkers on the probabilities of reporting 2+ or 3+
difficulties were then constructed from the estimated ordered
probit.Fig. 1. Path diagram forWe did not use all 12 specific biomarkers simultaneously as
predictors in model (1), for three reasons. First, there was a
significant loss of usable data when all markers are required to be
observed. Second, the full set of health measures (SAH and
biomarkers) displayed a substantial degree of collinearity, so there
would have been a further loss of statistical precision. A third
policy-relevant reason for considering each biomarker separately
is that, in practice, it is unlikely that any screening programme
would simultaneously check blood pressure, adiposity, blood
sugar, cholesterol, haemoglobin, hormone levels, liver, kidney and
lung function; so there is a practical interest in the predictive
power of each specific marker on its own. However, we also
separately used the two composite indexes for allostatic load and
CVD risk to consider the potential performance of more
comprehensive tests.
Although models like (1) are fairly standard in the literature,
they are vulnerable to measurement error bias. Biomarkers and
SAH are best seen as noisy indicators of the relevant health
concepts rather than direct observations of those concepts. SAH
may be subject to transient random variations in mood and
perception, while biomarkers are affected by random variations in
blood samples and measurement processes. Measurement noise
may bias estimates of predictive models like (1), usually causing
attenuation of the estimated impact of biomarkers and SAH. Our
alternative latent variable approach offers a way of dealing with
measurement error, by exploiting the multiplicity of biomarkers
that reflect to varying degrees the underlying health state. Our aim 2-factor LV model.
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indication of the predictive value of the biomarker information
beyond that contained in the SAH measure.
We used a two-factor structural LV model in which a latent
variable hi0 reflects a dimension of general health at baseline,
measured to varying degrees by SAH and the set of twelve
biomarkers (not the indexes for allostatic load and CVD risk). To
capture the incremental contribution of the biomarkers, we
specified a second latent health variable, bi0 representing any
dimension of baseline health that the biomarkers succeed in
measuring, but which is not captured by SAH. The outcome
variables, Di2, Di3, Di4, represent disability 2, 3 and 4 years after
baseline; the correlation between them is captured by an
unobserved random effect, ui, which may have different impacts
in different periods. The resulting model has the structure shown
in Fig. 1 and set out algebraically in the Supplement.
We used the estimated LV model to construct two predictive
probabilities, p1 and p2 based on different predictor sets, one
comprising the baseline covariates and SAH, the other expanded to
include also the twelve biomarkers. Omitting time subscripts, the
predictive probabilities are:
p1ðX; SÞ ¼ PðD ¼ 1jX; SÞ
p2ðX; S; B1 . . . B12Þ ¼ PðD ¼ 1jX; S; B1 . . . B12ÞTable 1
Four year ahead prediction models: % impact on mean disability prevalence of a stand
No. of functional difficulties re
Marker SAH 1 or morex 2 or mor
Nurse-collected measures
Waist/height ratio Excluded 20.2*** 25.1***
Included 11.1*** 13.9***
Grip strength Excluded 13.5*** 20.0***
Included 10.3*** 15.9***
Hypertension1 Excluded 14.3* 17.0*
Included 3.7 4.3 
Heart rate Excluded 13.3*** 16.3***
Included 9.9*** 12.1***
FVC2 Excluded 26.3*** 26.4***
Included 15.3*** 15.1***
FVC3 Excluded 25.6*** 26.3***
Included 14.7*** 15.1***
Blood-based biomarkers
HDL Excluded 20.8*** 22.4***
Included 15.5*** 15.9***
CRP Excluded 15.4*** 15.3***
Included 11.4*** 10.7***
HbA1c Excluded 14.8*** 16.3***
Included 10.4*** 11.2***
DHEAS Excluded 12.1** 12.5**
Included 9.1* 9.0 
EGFR Excluded 9.2* 10.6*
Included 7.6 8.4 
Hgb Excluded 5.2 6.4 
Included 3.0 3.6 
Albumin Excluded 10.8*** 13.9***
Included 7.6** 10.0**
Systemic risk indexes
Allostatic load Excluded 26.2*** 28.8***
Included 18.1*** 19.5***
CVD risk Excluded 20.4*** 22.4***
Included 13.4*** 14.4***
Sample proportion with disability 0.127 0.057 
x Derived from binary probit model.
† Derived from ordered probit model.
1 Impact of switch from non-hypertensive to hypertensive.
2 Without smoking covariate.
3 With smoking covariate.
* Statistical significance = 10%.
** Statistical significance = 5%.
*** Statistical significance = 1%.These were computed using Bayes’ rule as p1 ¼
E PðD ¼ 1; Sjh; b; u; XÞ½  = E PðSjh; b; u; XÞ½  and similarly for p2,
where the expectations with respect to the latent variables h, b,
u were approximated using Monte Carlo simulations with 100,000
replications.
4. Results
4.1. Simple predictive models
The results for model (1) at horizon t = 4 are presented in Table 1,
which shows the percentage impact on the predicted number of
people classified as disabled, of a 1-standard deviation increase in
the relevant biomarker. Columns three (one or more functional
difficulties), six (mobility) and seven (benefits) of the table were
derived from binary probit models; each cell in those columns was
based on a separate model for the relevant combination of
biomarker and disability measure. The cells in each row of columns
four and five came from the same ordered probit model for the
number of reported disabilities, with the impact of each biomarker
evaluated respectively at the 2+ and 3+ thresholds.
First note that, when SAH was excluded from the prediction
models, almost all biomarkers had substantial and statistically
significant (at least at the 5% level) predictive power. Theard deviation increase.
ported Mobility difficulty Benefit receipt
e† 3 or more†
28.0*** 38.1*** 33.7***
15.5*** 27.0*** 20.9***
25.1*** 18.0*** 32.6***
20.1*** 10.2 22.3***
18.8* 26.0*** 24.6*
4.7 11.8 11.4
18.1*** 15.9*** 16.1***
13.4*** 12.2*** 13.8***
28.3*** 31.1*** 39.3***
16.2*** 16.6** 22.0**
28.2*** 29.3*** 38.1***
16.2*** 15.5** 21.2**
24.8*** 21.1*** 8.3
17.5*** 15.0*** 1.2
16.4*** 19.6*** 20.2***
11.4*** 13.6*** 14.9***
17.9*** 14.0*** 10.0*
12.3*** 7.2* 3.5
13.8** 13.2* 10.0
9.9 7.0 3.0
11.7* 15.0** 9.2
9.2 11.5* 4.7
7.1 10.7* 16.7**
4.0 6.9 12.7*
15.3*** 19.4*** 16.2**
11.0*** 14.6*** 11.2*
30.0*** 39.1*** 25.4***
20.0*** 27.2*** 13.0*
23.3*** 33.6*** 24.1***
15.0*** 23.3*** 12.4*
0.026 0.072 0.042
Fig. 2. Estimated mean partial impacts of deterioration in SAH (change from
“excellent” to “poor/very poor”) and biomarkers (3-standard deviation change
centred on mean) on three binary indicators of disability 4 years later (Binary probit
model; percentage values are ratios of the biomarker effect to the SAH effect).
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estimates were insignificant at the 5% level for some disability
measures. When dummy variables for SAH status were introduced
into the model, the magnitudes of the biomarker coefficients fell,
mostly by 20–40%, but generally remained statistically significant.
Consequently, the SAH measure succeeded in capturing some of
the predictive power of the more objective measures, but far from
all.
There was some variation across biomarkers but, overall, the
nurse-collected and blood-based biomarkers were comparable in
terms of their predictive power. As expected, biomarkers for which
higher values represent worse health states had a positive
percentage impact on future disability and vice versa. Note that
lung function, which emerged as a strong influence on disability,
was not acting as a proxy for smoking, since inclusion of smoking
variables left the estimated effect practically unchanged. This is of
particular interest given recent evidence of the strong predictive
value of smoking on future disability (Bengtsson and Nilsson,
2018). To save space, the results for shorter prediction horizons (t
= 2, 3) are reported in the Supplement (Tables S6–S8); they show
systematic predictive power for most of the biomarkers, with the
effects mostly rising for longer prediction horizons.
To test whether the predictive role of each biomarker and/or
SAH vary by demographic and socioeconomic status (household
income, education and house tenure), we tested the relevant
interaction terms across our different model specifications. The
tests found no systematic differences in the predictive role of
biomarkers and SAH on future disability by age, gender or
socioeconomic status. For example, P-values for the interactions
of allostatic load with gender range between 0.471 and 0.716 across
the 4-year prediction models of the different disability outcomes;
for interactions with age, P-values ranged between 0.211 and
0.898. We also found no systematic interactions of our socioeco-
nomic status variables with allostatic load (P-values between 0.170
and 0.905).
Both composite biomarker measures gave strong effects, with
allostatic load having the strongest impact. The results for the
benefit receipt measure of disability were an interesting exception
to this: when SAH was included in the model, the magnitude of the
biomarker effect halved and retained significance only at the 10%
level. There may be two behavioural factors involved in that result.
One is justification bias – receipt of benefit may lead some
respondents to report a worse state of health in SAH to justify their
receipt of disability benefit. Alternatively, some people may be
reluctant to accept or admit that their health is poor, leading them
both to under-represent their current health difficulties in SAH and
avoid claiming their potential entitlement to disability benefit.
Both of these behaviours would be likely to strengthen the
empirical SAH effect relative to the estimated effect of allostatic
load or CVD risk indexes (which are more highly correlated with
SAH than individual biomarkers, and therefore more affected by
bias in SAH).
Figs. 2 and 3 compare the magnitude of the SAH and biomarker
impacts calculated from models where both SAH and the relevant
biomarker were use as predictors (together with the covariates X).
The SAH impact was calculated as the mean predicted impact of
switching the individual from the best (“excellent”) to worst
(“poor/very poor”) category of SAH; with the exception of the
binary hypertension marker, the biomarker effect was calculated
as the mean impact of switching from a value approximately 1.5
standard deviations better to 1.5 standard deviations worse than
the mean (between the 5th and 95th percentiles). Impacts are
calculated using the covariates X for each sampled individual and
then averaged.
Figs. 2 and 3 (see also Table S9 of the Supplement) show that the
biomarkers with statistically significant impacts shown in Table 1made predictive contributions of about 20–25% of the SAH effect in
most cases. For disability measures based on the number of
disabilities reported and mobility difficulties, allostatic load made
the largest contribution to prediction, both absolutely and as a
proportion of the SAH impact: the impact of a three standard
deviation change in allostatic load was approximately one third
that of the hypothetical SAH shift. For the mobility-based disability
criterion, allostatic load and WHR had the largest impacts in
absolute terms (roughly 40% of the SAH effect). In accordance with
the results in Table 1, allostatic load contributed less to the
prediction of benefit receipt, while the markers for grip strength,
Fig. 3. Estimated mean partial impacts of deterioration in SAH (change from
“excellent” to “poor/very poor”) and biomarkers (3-standard deviation change
centred on mean) on proportions reporting multiple functional difficulties 4 years
later (Ordered probit model; percentage values are ratios of the biomarker effect to
the SAH effect).
1 Note that sensitivity in this context is judged in relation to future disability and
may differ from the pattern of sensitivity that emerges relative to other future
outcomes.
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(around one third of the SAH effect).
Despite some differences between disability definitions in the
pattern of results, the overall conclusion seems robust –
biomarkers made a contribution to prediction of disability four
years ahead that is significant both statistically and in terms of
absolute magnitude. But that contribution is moderate in
comparison with the information contained in SAH.
There is a risk that the act of observation could change the
behaviour being observed – that formal or informal feedback about
the respondents’ biomarker levels may prompt additional GP
consultations and treatments for previously undiagnosed health
conditions, or behavioural changes (Zhao et al., 2013). In the
UKHLS, survey nurses were instructed not to discuss or interpret
respondents’ results in general or in relation to other people in the
survey, and blood tests results were not available to survey
participants. However, participants received a Measurement
Record Card with their blood pressures, height, weight, waist
circumference, percent body fat, and grip strength. The survey
protocol (National Centre for Social Research, 2010; McFall et al.,
2014) also specified tailored blood pressure feedback: respondents
were informed and advised to visit a GP within 2 months, 2 weeks
or 5 days if their blood pressure was mildly raised (140 systolic
blood pressure <160 or 90 diastolic blood pressure <100),
moderately raised (160–180 or 100–115) or considerably raised
(over 180 or over 115), respectively. Those with normal blood
pressure measurements received reassuring feedback.To explore the robustness of our results to the possibility of
feedback effects, we carried out a number of sensitivity analyses.
First, we added the categorial blood pressure feedback variable to
all our predictive models, and found that the results remained
practically identical to those presented in Table 1 and Figs. 2 and 3.
We also interacted the categorical blood pressure feedback
variable with our biomarkers, finding the interaction terms
statistically insignificant (at the 10% level) across all models. For
example, the P-values of interaction terms between our composite
biomarker measure (allostatic load) and the categorical blood
pressure feedback variable range from 0.678 and 0.904 across the
different disability outcome models. Thus the predictive role of
biomarkers does not systemically differ between those who were
informed of an elevated blood pressure and those with normal
blood pressure levels. We also re-estimated the prediction models
after excluding respondents who received feedback of mildly,
moderately or considerably raised blood pressure, showing only
minor differences to our base case results (compare Tables S9 and
S10 of the Supplement). Overall, this evidence alleviates concerns
about potential distortions from survey feedback effects –
although it is disappointing from the policy perspective that there
is so little evidence of feedback generating health improvements.
This bleak result is consistent with recent evidence suggesting that
screening programmes providing health information are often
relatively ineffective as a means of disease control (Chang et al.,
2018; Kim et al., 2019).
4.2. Do SAH and biomarkers measure the same thing? Latent variable
results
Our finding that SAH is a strong predictor of future disability
parallels similar evidence on mortality risks (Glei et al., 2014; Idler
and Benyamini, 1997; Jylhä, 2009), but it raises the issue of how
SAH relates to more objective biological aspects of health. SAH is a
subjective response that may reflect bodily sensations produced by
biological disease processes, but also potentially many other things
such as mood, self-image, past contacts with the healthcare
system, and health shocks to friends and relatives (Idler and
Benyamini, 1997; Jylhä, 2009). If used for policy purposes, SAH
might also be reported subconsciously or strategically to achieve or
justify a particular outcome. Even in its relation to biological
processes, SAH may be biased in particular directions since not all
disease processes are equally apparent to the sufferer.
No single biomarker or composite biomarker index can
plausibly act as a direct comparator in a conventional measure-
ment error validation study (Bound et al., 2001). A more productive
approach is to use biomarker information alongside SAH to
indicate the biological pathways to which SAH is insufficiently or
excessively sensitive.1We use the LV approach outlined in Section 3
to integrate SAH and biomarkers within an appropriately broad
measurement setting.
In practice biomarkers are also potentially error-prone meas-
ures, although not vulnerable to the behavioural reporting biases
that may affect SAH. Random measurement errors in biomarkers
used as predictors cause bias for the purposes of estimating causal
links between health and future disability. But that bias is not a
problem if we are concerned with prediction in the context of
policy applications such as screening or monitoring programmes,
since the biomarkers available to programme administrators are
subject to the same measurement error process – the (causally
biased) prediction model still gives the best prediction of future
Table 2
Estimated factor loadings (marginal impact on each health measure of a standard deviation increase in latent factor h or b).
Disability measure:
Any difficulty 2 difficulties Mobility difficulty Benefit receipt
Marker h b h b h b h b
SAHx 0.237 - 0.288 - 0.309 - 0.367 -
Nurse-measured markers
Waist/height ratio 0.498 0.171 0.512 0.189 0.504 0.207 0.540 0.193
Grip strenght 0.006† 0.829 0.043† 0.819 0.122 0.794 0.092 0.808
Hypertensionx 0.924 0.219 0.953 0.253 0.944 0.298 0.966 0.248
Heart rate 0.095 0.134 0.090 0.132 0.080 0.130 0.082 0.131
FVC 0.324 0.676 0.358 0.654 0.426 0.618 0.407 0.632
Blood-based biomarkers
HDL 0.100 0.377 0.111 0.380 0.083 0.375 0.128 0.382
CRP 0.185 0.060 0.205 0.044 0.215 0.033 0.235 0.031
HbA1c 0.424 0.061 0.426 0.087 0.425 0.100 0.443 0.088
DHEAS 0.527 0.309 0.799 0.284 0.576 0.248 0.558 0.272
EGFR 0.796 0.082 0.799 0.099 0.794 0.136 0.801 0.103
Hgb 0.131 0.639 0.105 0.634 0.051† 0.619 0.073 0.622
Albumin 0.326 0.273 0.346 0.253 0.375 0.225 0.377 0.235
† Loading not significantly different from zero at 5% (2-tailed test); all other loadings significant at 1%.
x For discrete indicators, marginal impact on the continuous latent variable underlying the observed indicator.
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administrator. However, to understand the relationship between
SAH and biological disease pathways we need estimates more
closely related to the true causal processes. An advantage of the LV
model is that allows for measurement noise in both SAH and
biomarkers and so avoids measurement error bias stemming from
classical random measurement error.
Tables 2 and 3 summarise results from the LV model. Table 2
gives the estimated factor loadings relating observable biomarkers
to the two latent dimensions of health. Except for the binary
hypertension measure, the loadings were normalised to give the
impacts of latent health on observed indicators in standard
deviation units. The loadings of the primary latent health factor hi0
are mostly as expected, with disability risk raised significantly by
WHR, hypertension, CRP and HbA1c; and lowered by grip strength,
lung capacity, HDL cholesterol, DHEAS, EGFR and Albumin.
The loadings on the second latent factor b must be interpreted
carefully in relation to the SAH loadings. For any given marker, if
the loading on h has the correct sign and the loading on b has the
same sign, then this implies that the health concept implicitly
captured by SAH understates the role of the biological pathway
which the marker measures. Under this interpretation, our finding
is that SAH strongly understates the importance of grip strength,Table 3
Summary statistics of predictive probabilities for alternative disability measures at
horizons t = 2, 3, 4, derived from estimated LV models.
Prediction
horizon
p1(X, S) p2(X, S, B1 . . . BJ)
Mean S.D. Mean S.D. corr(p1, p2)
One or more functional difficulties
t = 2 0.113 0.075 0.110 0.081 0.911
t = 3 0.124 0.087 0.120 0.093 0.908
t = 4 0.135 0.086 0.132 0.092 0.914
Two or more functional difficulties
t = 2 0.068 0.063 0.084 0.070 0.894
t = 3 0.067 0.066 0.082 0.074 0.891
t = 4 0.066 0.068 0.080 0.076 0.893
Mobility difficulty
t = 2 0.061 0.058 0.058 0.063 0.883
t = 3 0.069 0.064 0.066 0.070 0.874
t = 4 0.078 0.069 0.074 0.075 0.879
Receipt of disability benefit
t = 2 0.027 0.032 0.025 0.034 0.856
t = 3 0.031 0.039 0.028 0.042 0.852
t = 4 0.044 0.047 0.040 0.050 0.866lung function, DHEAS and liver function and weakly understates
the effect of CRP.
If the loading on h has the correct sign and the loading on b has
the opposite sign, then SAH can be interpreted as over-emphasis-
ing the pathway measured by the marker. This was the case for
WHR, hypertension and HDL cholesterol and, more weakly, for
HbA1c and EGFR.
In two cases, HR and Hgb, the loading on h was small, with an a
priori wrong sign, which was strongly reversed in the loading for b.
This finding can be interpreted to mean that, in these dimensions,
SAH is a potentially misleading indicator of future disability.
Our finding from the simple predictive model (1) was that
biomarkers provide significant and substantial predictive power
which is nevertheless moderate in relation to SAH. The same result
is also evident in results from the LV model. Table 3 gives summary
statistics for the predictive probabilities of future disability
conditional only on SAH and covariates (p1(X, S)), and conditional
on SAH, covariates and twelve biomarkers (p2(X, S, B1 . . . B12)).
These predictive probabilities were calculated for all disability
definitions and prediction horizons.
For three of the predictors, the mean predicted probability of
disability rose as we varied the prediction horizon from t = 2 to
t = 4, by approximately 20% (1 or more functional difficulties), 28%
(mobility problem) or 62% (benefit receipt). This rise in disability
risk over time is a natural reflection of the cumulative character of
disability prevalence. However, there was no such rise in
prevalence measured as the proportion of individuals reporting
two or more functional difficulties. For all four disability measures,
the predictive probabilities also became substantially more
variable (their standard deviations increased) as the prediction
horizon lengthened. For (almost) all of the predictions, there was a
rise in the variability of the predictor when we expanded the
baseline predictor set by adding the biomarkers. This reflects the
fact that adding biomarkers gives a more detailed and diverse
picture of each individual's disability risk. The correlations
between p1 and p2 were generally high, reflecting the good –
but not perfect – performance of SAH as a general health proxy.
5. Discussion and conclusions
We investigated the predictive power of objective nurse-
collected biomeasures and blood-based biomarkers for functional
disability, following individuals who reported no disability at
baseline for up to four years after collection of the health measures.
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disability, covering the existence and number of functional
disabilities, mobility difficulties and receipt of disability benefits.
For almost all of the biomarkers, we found 4-year-ahead
predictive effects that were substantial in magnitude and statisti-
cally significant. When SAH was introduced as a predictor alongside
the biomarkers, the magnitude of the biomarker effects fell, in most
cases by 20–40%, but remained important in magnitude and highly
statistically significant for most of the biomarkers examined.
Although there were some differences across biomarkers and
disability measures, we found that measures of adiposity, grip
strength, heart rate, lung functioning, cholesterol levels, inflamma-
tion, blood sugarand anaemia had strong predictive power for future
disability risk, over and above SAH.
How should we interpret these predictive results? Causality and
predictability are not the same thing, and there is a possibility that
the association between health measures and future disability
outcomes is partly the result of unobserved factors. In our view,
causality can never be established unambiguously in observational
data but, compared to cross-section analysis, the 4-year gap
between our initial health measure and disability outcomes makes
it much more likely that the predictive effects are causal rather
than proxy in nature. This separation in time removes the
possibility of reverse causation and weakens any ability of baseline
biomarker levels to proxy omitted heterogeneity. Moreover, the
most likely non-causal channels of association appear not to be
important here – we found no evidence of an effect of health
information fed back to respondents, nor of smoking behaviour on
disability outcomes. It is also important not to over-emphasise the
importance of causality. Predictability is extremely important for
some major policy purposes – for example, a successful screening
programme needs a good predictor to identify priority population
groups, and that does not necessarily require a complete structural
understanding of all the biochemical, behavioural and environ-
mental processes involved in determining the target outcomes.
In addition to simple predictive models, we also developed a
new latent variable approach capable of incorporating large
numbers of biomarkers and longitudinal observation of disability
outcomes, while allowing for measurement error in SAH and
biomarkers. This approach allowed us to identify distortions in
SAH as a measure of health, by detecting an additional predictive
factor that is revealed by the biomarkers but not by SAH. The
corresponding factor loadings indicate dimensions of biological
function that are given too much or too little weight by SAH in
predicting disability. We found that SAH is excessively sensitive to
the biological pathways reflected in adiposity, hypertension and
cholesterol, and insufficiently sensitive to strength, lung function,
hormonal balance and liver function.
Nevertheless, SAH emerged as a good general health proxy in
the sense that, when SAH and biomarkers were both used as
predictors, the estimated biomarker impacts on future disability,
although substantial absolutely, were moderate in comparison
with the effects of SAH. For example, using a composite summary
measure to proxy allostatic load (our strongest biomarker
predictor), we found that moving from the best (excellent) to
worst (fair/poor) category of SAH increased the risk of disability 4
years later by 5–18 percentage points on average, depending on the
disability concept used, while an increase in allostatic load from
the fifth to the lowest 95th percentile (roughly a 3-standard
deviation rise) increased disability risk by 2–7 points.
5.1. Limitations
Key strengths of our analysis come from its use of UKHLS data
which allowed us to use a large, nationally representative sample
covering all adult ages. The bio-social character of UKHLS provideda wide range of nurse-collected and blood-based biomarkers, in
addition to SAH, disability indicators and extensive measures of
household characteristics and socio-economic status. This adds
breadth and depth to the small body of evidence that already exists
on biomarkers as predictors of future disability. Existing studies
are more limited in terms of the range of biomarkers used and also
the study population, which is mainly restricted to older people,
nonrepresentative samples or specific patient groups (Brex et al.,
2002; Reuben et al., 1999; Baylis et al., 2013; Seeman et al., 1994).
As far as we are aware, ours is the first study that makes an explicit
evaluation of subjective SAH against objective biomarker informa-
tion in relation to disability.
Despite these advantages, there are limitations. First, the
available data follow individuals for a relatively short time horizon.
We have found evidence of a rise in the estimated effect of
biomarkers as the length of the prediction horizon increases,
suggesting that our results may understate the full long-term
predictive role of biomarkers. Second, functional disability is a
slippery, hard-to-measure concept and the measures used in our
analysis are necessarily limited. Our use of a range of alternative
disability measures alleviates these concerns to some degree, but a
complete solution requires further research. Finally, although we
used an unusually extensive set of biomarkers, the multidimen-
sional nature of the biomedical processes underlying disability
means that there may remain significant aspects of physical health
that are not covered by our analysis.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at https://doi.org/10.1016/j.ehb.2019.100814.
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